These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1941734)

  • 1. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
    Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
    J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
    O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
    Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
    Lindmark G; Kressner U; Bergström R; Glimelius B
    Anticancer Res; 1996; 16(2):895-8. PubMed ID: 8687147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
    Loibl S; Königs A; Kaufmann M; Costa SD; Bischoff J
    Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
    Nagele F; Vavra N; Kurz C; Sevelda P
    Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
    Oremek G; Sauer-Eppel H; Klepzig M
    Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
    Seifert M; Wierrani F; Kubista E; Spona J
    Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
    Bartel U; Johannsen B; Reiss H; Elling D
    Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum ferritin as a marker of therapeutic response in stage III and IV breast cancer.
    Williams MR; Turkes A; Pearson D; Griffiths K; Blamey RW
    Eur J Surg Oncol; 1990 Feb; 16(1):22-7. PubMed ID: 2137790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of serum cancer antigen 15-3 in breast cancer patients with isolated bone metastases.
    Turanli S; Cetin A
    Biomarkers; 2010 Aug; 15(5):418-23. PubMed ID: 20441435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.